KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.
Key Financial Performance
Revenue Achieved second consecutive quarter with more than $10 million in revenue, representing 27% year-over-year growth. The growth was driven by the core subcutaneous immunoglobulin (SCIg) business, which grew 30% due to international expansion, global share gains, and strong patient growth.
Domestic Revenue Declined 5% year-over-year due to a U.S. distributor reducing on-hand inventory levels, which temporarily impacted order volume.
International Revenue Grew by 230% year-over-year, driven by outsized stocking orders to support strong demand for prefilled conversions in Europe and a distributor transaction that inflated international revenue figures.
Gross Profit Increased by 21% year-over-year. Gross margin was 60.2%, a decrease of 320 basis points from the prior year due to higher manufacturing costs, lower yields, geographical customer mix, and tariff impacts.
Cash Flow Generated positive cash flow of $400,000, driven by lower net losses, higher revenues, and disciplined operating expense spending.
Year-to-Date Revenue Grew 22% to $30.2 million compared to $24.8 million in the prior year first 3 quarters. Operating expenses increased by 3%, and net losses were reduced by 50% from $4.5 million to $2.2 million.
Adjusted EBITDA Achieved positive adjusted EBITDA with a 109% improvement year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PST pipeline additions: Two new PST collaborations announced, expanding the pipeline and broadening patient reach.
Oncology infusion centers: Completed a U.S.-based oncology study validating KORU's value proposition, with plans for a 510(k) filing by end of 2025.
Non-Ig drugs: Nine active collaborations with four potential new drugs expected by 2026, including a new orthopedic collaboration with ForCast Ortho.
International market share: Increased from 10%-15% to 20% in the $60 million OUS SCIg market, with plans to grow to 40%.
Prefilled syringes in Europe: Majority of growth driven by conversions to prefilled syringes, simplifying administration and training.
Oncology infusion consumables: Projected market growth from $60 million in 2025 to $138 million by 2030.
Revenue growth: Achieved second consecutive quarter with over $10 million in revenue, a 27% year-over-year growth.
Gross margin: Maintained margins above 60%, despite manufacturing cost and tariff impacts.
Cash flow: Generated positive cash flow, ending the quarter with $8.5 million in cash.
SCIg market growth: Projected 9% annual growth over the next five years, driven by new patient diagnoses and broader SID diagnosis.
Pharma collaborations: Seven active collaborations with major Ig manufacturers, driving share gains and geographic expansion.
Oncology market entry: Progressing towards a 510(k) submission for oncology infusion systems, targeting commercial entry in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geographic Revenue Imbalance: The company experienced a geographic revenue imbalance due to domestic distributor inventory reductions, outsized international stocking orders, and cross-border distributor transactions. This created temporary distortions in revenue reporting and impacted domestic growth.
Manufacturing Costs and Margins: Higher manufacturing costs, lower yields, and tariff impacts led to a decrease in gross margins. While improvements are expected, the current cost structure poses a challenge to maintaining profitability.
Delayed Collaborations and Launches: Two previously announced collaborations had their launch dates pushed to 2027, and a rare disease candidate was delayed by one quarter due to FDA requests for additional testing data. These delays could impact the company's pipeline momentum and revenue projections.
Regulatory and Market Entry Risks: The company faces regulatory hurdles, including upcoming 510(k) submissions for oncology and other drugs. Delays or rejections could hinder market entry and growth in new therapeutic areas.
International Market Risks: While international growth is strong, it is heavily reliant on prefilled syringe conversions in Europe. Any disruptions in this trend or competitive pressures could impact growth projections.
Tariff and Supply Chain Challenges: Tariff impacts and supply chain dependencies, particularly in international markets, pose risks to cost management and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Achieved second consecutive quarter with over $10 million in revenue, representing 27% year-over-year growth. Core SCIg business grew 30%, driven by international expansion, global share gains, and patient growth.
Pipeline Expansion: Announced 2 new PST collaborations and advanced oncology infusion center expansion with a U.S.-based study. On track for a 510(k) filing by the end of 2025.
International Market Share: Increased international market share from 10%-15% to 20% of the $60 million OUS SCIg market. Targeting 40% market share in the coming years, representing a $10-$20 million opportunity.
Oncology Infusion Space: Completed U.S. pilot study for oncology infusion, achieving 100% success rate and high satisfaction among nurses and patients. Anticipated commercial market entry in the second half of 2026.
Non-Ig Drug Pipeline: 9 active collaborations with 4 potential new drugs expected by the end of 2026. Estimated commercial potential of up to $10 million by 2028.
Full Year Revenue Guidance: Raised to $40.5 million to $41 million, representing 20%-22% growth.
Gross Margins: Reiterated guidance for gross margins in the range of 61%-63%.
Cash Flow: Reiterated positive cash flow from operations, expecting to end the year with at least $8.2 million in cash.
SCIg Market Growth: External forecasts project SCIg market growth of approximately 9% annually over the next 5 years, outpacing the IVIg segment.
Oncology Infusion Market: Projected to grow from $60 million in 2025 to $138 million by 2030. KORU plans to enter this market in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the nurse feedback and workflow efficiency in the oncology setting?
A:The clinical study was conducted in 5 diverse U.S. clinics, showing high nursing and patient satisfaction (90%+). 70% of nurses reported improved workflow efficiency, being able to multi-task while using the pump, unlike the manual syringe push method. This allows clinics to improve patient throughput.
Q:What is the status of the reimbursement model for the oncology setting?
A:The reimbursement codes for administering drugs in infusion clinics using a pump already exist, so no additional work is needed on this front. The company is confident about the opportunity in the oncology market.
Q:Can you provide a breakout of revenues per line item for Q4 and initial thoughts on 2026?
A:For Q4, the U.S. business is expected to account for around 70% of revenue, with international business contributing 23%-24%, and the remainder from the PST business. For 2026, while exact guidance is not provided, the company is optimistic about achieving sustainable 20%+ growth, driven by prefills, international expansion, oncology, and new drugs.
Q:Can you provide more details on the EU market and the transition to prefilled syringes (PFS)?
A:The international expansion is expected to double the company's share position, representing a $10-$20 million opportunity, primarily driven by prefills. The transition to PFS in Europe is a major growth driver, with studies showing a 50% reduction in steps compared to electronic pumps. The company is working on specific go-to-market plans for each country.
Q:What are the market growth dynamics for SCIg and the impact of flu season?
A:The underlying rate of patient diagnosis is increasing, with acceleration quarter-to-quarter. Flu season may lead to more PID diagnoses, but it typically requires multiple infections before diagnosis. Secondary Immunodeficiency (SID) is also growing due to aging populations and cancer treatments, with trials for SID reimbursement underway.
Q:What is the outlook for gross margins over the next 12-18 months?
A:The company aims to maintain margins at 61%-63% despite international mix changes and tariffs, with a long-term goal of reaching 65%+. Operational excellence programs and manufacturing efficiencies are being implemented to support this goal.
Q:What is the status of the Japan market?
A:Sales in Japan are expected to be $300,000-$500,000 this year. The market is primarily in-hospital, and growth is expected to take longer. However, the broader prefill opportunity is currently a higher priority.
Q:Can you clarify the U.S. core growth and SCIg market growth in Q3?
A:U.S. core growth was approximately 14% year-over-year after adjusting for ordering dynamics. SCIg market growth in Q1 and Q2 was 8%-9%, with acceleration driven by PID and SID.
Q:What is the cadence for prefilled syringe rollouts in Europe?
A:The rollout is expected to be completed in major markets by the end of 2026, with decisions made on a country-by-country basis. The company is working on specific plans to ensure a smooth transition.
Q:How will the company prevent cross-geography ordering issues in the future?
A:The company has implemented measures to ensure product goes to the correct markets as per contracts, including requiring tracings and protecting pricing per market. The issue has been corrected and is not expected to recur.
Q:Review of Unclear Management Responses
A:Management avoided providing exact guidance for 2026, only stating that they are optimistic about achieving 20%+ growth. They also did not provide specific details on the next countries for prefilled syringe rollouts in Europe, citing the need for country-specific plans. Additionally, they did not have Q3 SCIg market growth numbers yet, as these lag by a couple of months.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EU
FDA
Freedom
Ig collaboration
PST
SID
administration
adoption
area
business
conversion
core strength
decrease
demand
entry oncology
factor
highlight
imbalance
immunoglobulin
launch date
market position
market vial
momentum SCIg
nurse patient
oncology drug
oncology infusion
pharma partner
push nurse
shift
space
start cash
study
syringe push
syrinx
tariff
therapy market
timing
track
treatment
value proposition
KRMD Transcript
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and a 40% rise in net income, alongside improved gross margins. These indicators, coupled with positive cash flow, suggest robust financial health. Despite the absence of strategic updates, the financial metrics and optimistic forward-looking statements indicate potential for positive stock movement. The lack of negative sentiment in the Q&A further supports a positive outlook, likely resulting in a 2% to 8% stock price increase over the next two weeks.
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlighted strong growth in prefilled syringes, a strategic focus on expanding international markets, and a positive cash flow reinvestment plan. Although there were some delays and uncertainties, the company is mitigating these effectively. The Q&A section revealed optimism about future growth, particularly with new product launches and international expansion. Overall, the sentiment is positive, with potential for stock price appreciation given the strong business fundamentals and strategic initiatives.
KRMD Slides
KRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
